Which has higher earnings and valuation, IMDX or CLYM?

Oncocyte has higher revenue and earnings than Climb Bio. Climb Bio is trading at a lower price-to-earnings ratio than Oncocyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oncocyte $4.05M 36.60 -$50.22M -$1.48 N/A Climb Bio N/A N/A -$59.85M -$0.78 N/A

Is IMDX or CLYM more profitable?

Climb Bio has a net margin of 0.00% compared to Oncocyte's net margin of -2,454.64%. Oncocyte's return on equity of 0.00% beat Climb Bio's return on equity. Company Net Margins Return on Equity Return on Assets Oncocyte -2,454.64% N/A -96.96% Climb Bio N/A -31.45% -30.39%

Is IMDX or PRME more profitable?

Oncocyte has a net margin of -2,454.64% compared to Prime Medicine's net margin of -4,917.55%. Oncocyte's return on equity of 0.00% beat Prime Medicine's return on equity. Company Net Margins Return on Equity Return on Assets Oncocyte -2,454.64% N/A -96.96% Prime Medicine -4,917.55% -188.82% -60.97%

Oncocyte (IMDX) Competitors

$4.59 -0.49 (-9.65%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$4.79 +0.20 (+4.31%)

As of 08:15 AM Eastern

Compare

IMDX vs. CLYM, CADL, ALLO, TECX, and PRME

Should you buy Oncocyte stock or one of its competitors? MarketBeat compares Oncocyte with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Oncocyte include Climb Bio (CLYM), Candel Therapeutics (CADL), Allogene Therapeutics (ALLO), Tectonic Therapeutic (TECX), and Prime Medicine (PRME). These companies are all part of the "pharmaceutical products" industry.

How does Oncocyte compare to Climb Bio?

Oncocyte (NASDAQ:IMDX) and Climb Bio (NASDAQ:CLYM) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends, institutional ownership and media sentiment.

Oncocyte presently has a consensus price target of $12.00, indicating a potential upside of 161.44%. Climb Bio has a consensus price target of $21.73, indicating a potential upside of 64.48%. Given Oncocyte's higher possible upside, equities analysts plainly believe Oncocyte is more favorable than Climb Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncocyte	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	3 Strong Buy rating(s)	3.07

Oncocyte has higher revenue and earnings than Climb Bio. Climb Bio is trading at a lower price-to-earnings ratio than Oncocyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncocyte	$4.05M	36.60	-$50.22M	-$1.48	N/A
Climb Bio	N/A	N/A	-$59.85M	-$0.78	N/A

55.4% of Oncocyte shares are owned by institutional investors. Comparatively, 69.8% of Climb Bio shares are owned by institutional investors. 2.2% of Oncocyte shares are owned by insiders. Comparatively, 2.6% of Climb Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Climb Bio has a net margin of 0.00% compared to Oncocyte's net margin of -2,454.64%. Oncocyte's return on equity of 0.00% beat Climb Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncocyte	-2,454.64%	N/A	-96.96%
Climb Bio	N/A	-31.45%	-30.39%

Oncocyte has a beta of 1.76, meaning that its stock price is 76% more volatile than the broader market. Comparatively, Climb Bio has a beta of 0.07, meaning that its stock price is 93% less volatile than the broader market.

In the previous week, Climb Bio had 1 more articles in the media than Oncocyte. MarketBeat recorded 2 mentions for Climb Bio and 1 mentions for Oncocyte. Oncocyte's average media sentiment score of 1.87 beat Climb Bio's score of 0.83 indicating that Oncocyte is being referred to more favorably in the media.

Company	Overall Sentiment
Oncocyte	Very Positive
Climb Bio	Positive

Summary

Climb Bio beats Oncocyte on 9 of the 16 factors compared between the two stocks.

How does Oncocyte compare to Candel Therapeutics?

Oncocyte (NASDAQ:IMDX) and Candel Therapeutics (NASDAQ:CADL) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

In the previous week, Candel Therapeutics had 4 more articles in the media than Oncocyte. MarketBeat recorded 5 mentions for Candel Therapeutics and 1 mentions for Oncocyte. Oncocyte's average media sentiment score of 1.87 beat Candel Therapeutics' score of 1.03 indicating that Oncocyte is being referred to more favorably in the media.

Company	Overall Sentiment
Oncocyte	Very Positive
Candel Therapeutics	Positive

Candel Therapeutics has lower revenue, but higher earnings than Oncocyte. Candel Therapeutics is trading at a lower price-to-earnings ratio than Oncocyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncocyte	$4.05M	36.60	-$50.22M	-$1.48	N/A
Candel Therapeutics	N/A	N/A	-$38.18M	-$0.98	N/A

Oncocyte presently has a consensus target price of $12.00, indicating a potential upside of 161.44%. Candel Therapeutics has a consensus target price of $18.57, indicating a potential upside of 92.65%. Given Oncocyte's higher possible upside, research analysts plainly believe Oncocyte is more favorable than Candel Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncocyte	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

55.4% of Oncocyte shares are owned by institutional investors. Comparatively, 13.9% of Candel Therapeutics shares are owned by institutional investors. 2.2% of Oncocyte shares are owned by company insiders. Comparatively, 14.3% of Candel Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Oncocyte has a beta of 1.76, indicating that its share price is 76% more volatile than the broader market. Comparatively, Candel Therapeutics has a beta of -0.52, indicating that its share price is 152% less volatile than the broader market.

Candel Therapeutics has a net margin of 0.00% compared to Oncocyte's net margin of -2,454.64%. Oncocyte's return on equity of 0.00% beat Candel Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncocyte	-2,454.64%	N/A	-96.96%
Candel Therapeutics	N/A	-60.42%	-41.33%

Summary

Candel Therapeutics beats Oncocyte on 8 of the 15 factors compared between the two stocks.

How does Oncocyte compare to Allogene Therapeutics?

Oncocyte (NASDAQ:IMDX) and Allogene Therapeutics (NASDAQ:ALLO) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, profitability, institutional ownership, dividends, analyst recommendations and valuation.

Oncocyte currently has a consensus target price of $12.00, suggesting a potential upside of 161.44%. Allogene Therapeutics has a consensus target price of $8.52, suggesting a potential upside of 341.57%. Given Allogene Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Allogene Therapeutics is more favorable than Oncocyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncocyte	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69

Allogene Therapeutics has a net margin of 0.00% compared to Oncocyte's net margin of -2,454.64%. Oncocyte's return on equity of 0.00% beat Allogene Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncocyte	-2,454.64%	N/A	-96.96%
Allogene Therapeutics	N/A	-56.45%	-40.36%

In the previous week, Allogene Therapeutics had 2 more articles in the media than Oncocyte. MarketBeat recorded 3 mentions for Allogene Therapeutics and 1 mentions for Oncocyte. Oncocyte's average media sentiment score of 1.87 beat Allogene Therapeutics' score of 1.19 indicating that Oncocyte is being referred to more favorably in the media.

Company	Overall Sentiment
Oncocyte	Very Positive
Allogene Therapeutics	Positive

Oncocyte has higher revenue and earnings than Allogene Therapeutics. Oncocyte is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncocyte	$4.05M	36.60	-$50.22M	-$1.48	N/A
Allogene Therapeutics	$20K	33,306.98	-$190.89M	-$0.77	N/A

55.4% of Oncocyte shares are owned by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are owned by institutional investors. 2.2% of Oncocyte shares are owned by company insiders. Comparatively, 13.2% of Allogene Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Oncocyte has a beta of 1.76, suggesting that its stock price is 76% more volatile than the broader market. Comparatively, Allogene Therapeutics has a beta of 0.46, suggesting that its stock price is 54% less volatile than the broader market.

Summary

Allogene Therapeutics beats Oncocyte on 12 of the 17 factors compared between the two stocks.

How does Oncocyte compare to Tectonic Therapeutic?

Oncocyte (NASDAQ:IMDX) and Tectonic Therapeutic (NASDAQ:TECX) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, media sentiment, valuation, risk and analyst recommendations.

Tectonic Therapeutic has a net margin of 0.00% compared to Oncocyte's net margin of -2,454.64%. Oncocyte's return on equity of 0.00% beat Tectonic Therapeutic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncocyte	-2,454.64%	N/A	-96.96%
Tectonic Therapeutic	N/A	-32.33%	-30.92%

Oncocyte has a beta of 1.76, suggesting that its stock price is 76% more volatile than the broader market. Comparatively, Tectonic Therapeutic has a beta of 3.21, suggesting that its stock price is 221% more volatile than the broader market.

55.4% of Oncocyte shares are owned by institutional investors. Comparatively, 62.6% of Tectonic Therapeutic shares are owned by institutional investors. 2.2% of Oncocyte shares are owned by company insiders. Comparatively, 39.8% of Tectonic Therapeutic shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Oncocyte presently has a consensus target price of $12.00, indicating a potential upside of 161.44%. Tectonic Therapeutic has a consensus target price of $79.40, indicating a potential upside of 131.22%. Given Oncocyte's higher possible upside, equities analysts plainly believe Oncocyte is more favorable than Tectonic Therapeutic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncocyte	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Tectonic Therapeutic	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00

Oncocyte has higher revenue and earnings than Tectonic Therapeutic. Tectonic Therapeutic is trading at a lower price-to-earnings ratio than Oncocyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncocyte	$4.05M	36.60	-$50.22M	-$1.48	N/A
Tectonic Therapeutic	N/A	N/A	-$74.15M	-$4.46	N/A

In the previous week, Tectonic Therapeutic had 1 more articles in the media than Oncocyte. MarketBeat recorded 2 mentions for Tectonic Therapeutic and 1 mentions for Oncocyte. Oncocyte's average media sentiment score of 1.87 beat Tectonic Therapeutic's score of 1.61 indicating that Oncocyte is being referred to more favorably in the media.

Company	Overall Sentiment
Oncocyte	Very Positive
Tectonic Therapeutic	Very Positive

Summary

Tectonic Therapeutic beats Oncocyte on 9 of the 16 factors compared between the two stocks.

How does Oncocyte compare to Prime Medicine?

Oncocyte (NASDAQ:IMDX) and Prime Medicine (NASDAQ:PRME) are both small-cap manufacturing companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, media sentiment, profitability, analyst recommendations, risk and valuation.

Oncocyte currently has a consensus target price of $12.00, indicating a potential upside of 161.44%. Prime Medicine has a consensus target price of $7.53, indicating a potential upside of 114.57%. Given Oncocyte's higher possible upside, equities analysts plainly believe Oncocyte is more favorable than Prime Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncocyte	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Prime Medicine	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Oncocyte has higher earnings, but lower revenue than Prime Medicine. Oncocyte is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncocyte	$4.05M	36.60	-$50.22M	-$1.48	N/A
Prime Medicine	$4.63M	136.93	-$201.14M	-$1.23	N/A

In the previous week, Prime Medicine had 7 more articles in the media than Oncocyte. MarketBeat recorded 8 mentions for Prime Medicine and 1 mentions for Oncocyte. Oncocyte's average media sentiment score of 1.87 beat Prime Medicine's score of 0.85 indicating that Oncocyte is being referred to more favorably in the media.

Company	Overall Sentiment
Oncocyte	Very Positive
Prime Medicine	Positive

Oncocyte has a beta of 1.76, indicating that its share price is 76% more volatile than the broader market. Comparatively, Prime Medicine has a beta of 2.26, indicating that its share price is 126% more volatile than the broader market.

55.4% of Oncocyte shares are owned by institutional investors. Comparatively, 70.4% of Prime Medicine shares are owned by institutional investors. 2.2% of Oncocyte shares are owned by company insiders. Comparatively, 16.0% of Prime Medicine shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Oncocyte has a net margin of -2,454.64% compared to Prime Medicine's net margin of -4,917.55%. Oncocyte's return on equity of 0.00% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncocyte	-2,454.64%	N/A	-96.96%
Prime Medicine	-4,917.55%	-188.82%	-60.97%

Summary

Prime Medicine beats Oncocyte on 12 of the 17 factors compared between the two stocks.

Get Oncocyte News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMDX vs. The Competition

Export

Metric	Oncocyte	In Vitro, In Vivo Diagnostic Substances Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$164.03M	$386.27M	$5.06B	$12.61B
Dividend Yield	N/A	N/A	27.48%	8.00%
P/E Ratio	-3.10	N/A	23.70	24.26
Price / Sales	36.60	101.22	146.10	117.88
Price / Cash	N/A	210.98	31.98	49.36
Price / Book	-4.17	24.07	12.23	6.29
Net Income	-$50.22M	-$18.48M	$118.20M	$330.66M
7 Day Performance	-6.90%	-9.07%	-1.63%	-1.35%
1 Month Performance	-18.18%	-18.06%	-1.94%	-0.64%
1 Year Performance	N/A	-55.90%	8.97%	19.08%

Oncocyte Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMDX Oncocyte	3.2982 of 5 stars	$4.59 -9.6%	$12.00 +161.4%	N/A	$164.03M	$4.05M	N/A	120	High Trading Volume
CLYM Climb Bio	3.0254 of 5 stars	$13.27 +2.9%	$21.73 +63.7%	+864.2%	$738.69M	N/A	N/A	9
CADL Candel Therapeutics	3.3327 of 5 stars	$10.03 +2.0%	$18.00 +79.5%	+65.9%	$720.25M	N/A	N/A	60	Analyst Forecast
ALLO Allogene Therapeutics	2.4023 of 5 stars	$2.09 +0.5%	$8.52 +307.8%	+50.8%	$717.92M	$20K	N/A	310	News Coverage Positive News
TECX Tectonic Therapeutic	2.8784 of 5 stars	$35.22 -7.1%	$79.40 +125.4%	+51.7%	$715.71M	N/A	N/A	120	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMDX) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Oncocyte (IMDX) Competitors

IMDX vs. CLYM, CADL, ALLO, TECX, and PRME

How does Oncocyte compare to Climb Bio?

Summary

How does Oncocyte compare to Candel Therapeutics?

Summary

How does Oncocyte compare to Allogene Therapeutics?

Summary

How does Oncocyte compare to Tectonic Therapeutic?

Summary

How does Oncocyte compare to Prime Medicine?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMDX vs. The Competition

Oncocyte Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Oncocyte (IMDX) Competitors

IMDX vs. CLYM, CADL, ALLO, TECX, and PRME

How does Oncocyte compare to Climb Bio?

Do analysts recommend IMDX or CLYM?

Which has higher earnings and valuation, IMDX or CLYM?

Do institutionals and insiders have more ownership in IMDX or CLYM?

Is IMDX or CLYM more profitable?

Which has more volatility and risk, IMDX or CLYM?

Does the media prefer IMDX or CLYM?

Summary

How does Oncocyte compare to Candel Therapeutics?

Does the media prefer IMDX or CADL?

Which has better valuation and earnings, IMDX or CADL?

Do analysts rate IMDX or CADL?

Do insiders and institutionals have more ownership in IMDX or CADL?

Which has more volatility & risk, IMDX or CADL?

Is IMDX or CADL more profitable?

Summary

How does Oncocyte compare to Allogene Therapeutics?

Do analysts recommend IMDX or ALLO?

Is IMDX or ALLO more profitable?

Does the media prefer IMDX or ALLO?

Which has better valuation & earnings, IMDX or ALLO?

Do insiders & institutionals hold more shares of IMDX or ALLO?

Which has more volatility & risk, IMDX or ALLO?

Summary

How does Oncocyte compare to Tectonic Therapeutic?

Is IMDX or TECX more profitable?

Which has more volatility & risk, IMDX or TECX?

Do institutionals and insiders believe in IMDX or TECX?

Do analysts prefer IMDX or TECX?

Which has higher earnings & valuation, IMDX or TECX?

Does the media refer more to IMDX or TECX?

Summary

How does Oncocyte compare to Prime Medicine?

Do analysts recommend IMDX or PRME?

Which has stronger earnings & valuation, IMDX or PRME?

Does the media prefer IMDX or PRME?

Which has more volatility and risk, IMDX or PRME?

Do institutionals and insiders believe in IMDX or PRME?

Is IMDX or PRME more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMDX vs. The Competition

Oncocyte Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools